title: Mycobacterium chelonae infection associated with adalimumab therapy.
authors.forename: F
authors.initials: F
authors.lastname: Díaz
authors.forename: J C
authors.initials: JC
authors.lastname: Urkijo
authors.forename: F
authors.initials: F
authors.lastname: Mendoza
authors.forename: J M
authors.initials: JM
authors.lastname: de la Viuda
authors.forename: M
authors.initials: M
authors.lastname: Blanco
authors.forename: A
authors.initials: A
authors.lastname: Unzurrunzaga
authors.forename: R
authors.initials: R
authors.lastname: Ayarza
mesh_terms: D000068879:Adalimumab; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy; D005260:Female; D006801:Humans; D009165:Mycobacterium Infections, Nontuberculous / Q000139:chemically induced / Q000175:diagnosis* / Q000517:prevention & control; D016926:Mycobacterium chelonae; D009894:Opportunistic Infections / Q000139:chemically induced / Q000175:diagnosis* / Q000517:prevention & control; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000502:physiology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab